Elevated labile iron in castration–resistant prostate cancer is targetable with ferrous iron–activatable antiandrogen therapy

Document Details

Document Type
Pub Defense Publication
Publication Date
Mar 01, 2023
Source ID
10.1016/j.ejmech.2023.115110

Entities

People

  • Adam R Renslo
  • Garima Kumar
  • Hyunjung Kim
  • Michael J. Evans
  • Nima Hooshdaran
  • Ryan L. Gonciarz
  • Sasank Sakhamuri

Organizations

  • American Cancer Society
  • Congressionally Directed Medical Research Programs
  • National Institute of Biomedical Imaging and Bioengineering
  • National Institutes of Health
  • University of California, San Francisco